JP7486423B2 - 糖尿病、肝炎、および／または炎症性肝疾患を治療するための方法 - Google Patents

糖尿病、肝炎、および／または炎症性肝疾患を治療するための方法 Download PDF

Info

Publication number
JP7486423B2
JP7486423B2 JP2020537722A JP2020537722A JP7486423B2 JP 7486423 B2 JP7486423 B2 JP 7486423B2 JP 2020537722 A JP2020537722 A JP 2020537722A JP 2020537722 A JP2020537722 A JP 2020537722A JP 7486423 B2 JP7486423 B2 JP 7486423B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
diabetes
type
onset
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020537722A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511296A (ja
JP2021511296A5 (enExample
Inventor
ラインス，マイケル，エー．
ツェン，ユイ－ホア
ラインス，マシュー，ディー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Connecticut
Original Assignee
University of Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Connecticut filed Critical University of Connecticut
Publication of JP2021511296A publication Critical patent/JP2021511296A/ja
Publication of JP2021511296A5 publication Critical patent/JP2021511296A5/ja
Priority to JP2024002422A priority Critical patent/JP2024028454A/ja
Application granted granted Critical
Publication of JP7486423B2 publication Critical patent/JP7486423B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020537722A 2018-01-17 2019-01-17 糖尿病、肝炎、および／または炎症性肝疾患を治療するための方法 Active JP7486423B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024002422A JP2024028454A (ja) 2018-01-17 2024-01-11 糖尿病、肝炎、および／または炎症性肝疾患を治療するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862618332P 2018-01-17 2018-01-17
US62/618,332 2018-01-17
PCT/US2019/013934 WO2019143767A1 (en) 2018-01-17 2019-01-17 Methods for treating diabetes, hepatitis, and/or inflammatory liver disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024002422A Division JP2024028454A (ja) 2018-01-17 2024-01-11 糖尿病、肝炎、および／または炎症性肝疾患を治療するための方法

Publications (3)

Publication Number Publication Date
JP2021511296A JP2021511296A (ja) 2021-05-06
JP2021511296A5 JP2021511296A5 (enExample) 2022-01-04
JP7486423B2 true JP7486423B2 (ja) 2024-05-17

Family

ID=65324621

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020537722A Active JP7486423B2 (ja) 2018-01-17 2019-01-17 糖尿病、肝炎、および／または炎症性肝疾患を治療するための方法
JP2024002422A Pending JP2024028454A (ja) 2018-01-17 2024-01-11 糖尿病、肝炎、および／または炎症性肝疾患を治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024002422A Pending JP2024028454A (ja) 2018-01-17 2024-01-11 糖尿病、肝炎、および／または炎症性肝疾患を治療するための方法

Country Status (20)

Country Link
US (3) US11866488B2 (enExample)
EP (2) EP3740282B1 (enExample)
JP (2) JP7486423B2 (enExample)
KR (1) KR20200110659A (enExample)
CN (2) CN120267797A (enExample)
AU (2) AU2019209491B2 (enExample)
BR (1) BR112020014346A2 (enExample)
CA (1) CA3088661A1 (enExample)
EA (1) EA202091533A1 (enExample)
ES (1) ES3033317T3 (enExample)
HR (1) HRP20250727T1 (enExample)
HU (1) HUE072418T2 (enExample)
IL (2) IL276097B2 (enExample)
MX (1) MX2020007384A (enExample)
PH (1) PH12020551076A1 (enExample)
PL (1) PL3740282T3 (enExample)
RS (1) RS66918B1 (enExample)
SG (1) SG11202006421RA (enExample)
SM (1) SMT202500233T1 (enExample)
WO (1) WO2019143767A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020234718A1 (en) 2019-03-13 2023-05-18 Tearsolutions, Inc. Compositions and methods for promoting islet viability and enhancing insulin secretion
AU2020315367A1 (en) 2019-07-15 2022-02-03 University Of Connecticut Metallothionein antibodies and their use
CN110551726B (zh) * 2019-09-06 2021-04-09 上海市肺科医院 一种结核杆菌阿拉伯半乳聚糖适配子及其应用
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
KR102191405B1 (ko) * 2020-09-15 2020-12-16 주식회사 에이스바이오메드 간 질환 예방 또는 치료용 조성물
CN115317502B (zh) * 2021-12-21 2023-07-07 青岛市市立医院 一种线性硬毛藻提取的粗多糖在制备非酒精性脂肪性肝药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013543504A (ja) 2010-10-14 2013-12-05 イムナール アクティエボラーグ Ａｈｒ活性化因子としての１，２‐ジヒドロ‐４‐ヒドロキシ‐２‐オキソ‐キノリン‐３‐カルボキシアニリド
WO2014172606A1 (en) 2013-04-19 2014-10-23 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins
US20170143798A1 (en) 2014-05-27 2017-05-25 The University Of Queensland Modulation of cellular stress
JP2017523790A (ja) 2014-08-07 2017-08-24 レグルス セラピューティクス インコーポレイテッド 代謝障害のためのマイクロｒｎａの標的化

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20030007973A1 (en) 2001-06-22 2003-01-09 Lynes Michael A. Methods and compositions for manipulation of the immune response using anti-metallothionein antibody
WO2007012188A1 (en) 2005-07-27 2007-02-01 Qinghua Wang GLP/1/EXENDM 4 IgG Fc FUSION CONSTRUCTS FOR TREATMENT OF DIABETES
CN102725312B (zh) * 2009-10-20 2014-10-01 佐治亚州立大学研究基金会公司 用于糖尿病治疗和β细胞成像的蛋白药物
CA2840282C (en) * 2011-07-08 2018-11-13 Universiteit Gent Use of antagonists targeting metallothionein to treat intestinal inflammation
TR201402685A1 (tr) 2014-03-06 2015-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vildagliptinin farmasotik formulasyonları.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013543504A (ja) 2010-10-14 2013-12-05 イムナール アクティエボラーグ Ａｈｒ活性化因子としての１，２‐ジヒドロ‐４‐ヒドロキシ‐２‐オキソ‐キノリン‐３‐カルボキシアニリド
WO2014172606A1 (en) 2013-04-19 2014-10-23 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins
US20170143798A1 (en) 2014-05-27 2017-05-25 The University Of Queensland Modulation of cellular stress
JP2017523790A (ja) 2014-08-07 2017-08-24 レグルス セラピューティクス インコーポレイテッド 代謝障害のためのマイクロｒｎａの標的化

Also Published As

Publication number Publication date
EP3740282C0 (en) 2025-03-26
CN111801140B (zh) 2025-05-16
WO2019143767A1 (en) 2019-07-25
IL316486A (en) 2024-12-01
EP3740282B1 (en) 2025-03-26
US20240025981A1 (en) 2024-01-25
EP4596042A3 (en) 2025-11-05
KR20200110659A (ko) 2020-09-24
AU2022215285A1 (en) 2022-09-29
JP2021511296A (ja) 2021-05-06
AU2019209491A1 (en) 2020-07-23
JP2024028454A (ja) 2024-03-04
IL276097A (en) 2020-08-31
EP4596042A2 (en) 2025-08-06
EP3740282A1 (en) 2020-11-25
IL276097B2 (en) 2025-04-01
CN111801140A (zh) 2020-10-20
AU2022215285B2 (en) 2024-08-29
PH12020551076A1 (en) 2021-08-16
AU2019209491B2 (en) 2022-05-19
PL3740282T3 (pl) 2025-07-21
IL276097B1 (en) 2024-12-01
US20200369757A1 (en) 2020-11-26
EA202091533A1 (ru) 2020-11-16
ES3033317T3 (en) 2025-08-01
HUE072418T2 (hu) 2025-11-28
US20240067710A1 (en) 2024-02-29
CN120267797A (zh) 2025-07-08
RS66918B1 (sr) 2025-07-31
SMT202500233T1 (it) 2025-07-22
US11866488B2 (en) 2024-01-09
BR112020014346A2 (pt) 2020-12-08
CA3088661A1 (en) 2019-07-25
SG11202006421RA (en) 2020-08-28
MX2020007384A (es) 2020-10-19
HRP20250727T1 (hr) 2025-10-24

Similar Documents

Publication Publication Date Title
JP7486423B2 (ja) 糖尿病、肝炎、および／または炎症性肝疾患を治療するための方法
JP6633108B2 (ja) 脂肪組織の集積を処置するための組成物および方法
CN102548573B (zh) Nkg2d抑制剂在治疗心血管和代谢疾病如2型糖尿病中的用途
CN102834413A (zh) 代谢障碍的治疗
CN119604532A (zh) 用于抗胰岛素受体抗体的制剂及其用途
WO2017062693A1 (en) Methods for treating rare genetic disorders using glucagon receptor antagonistic antibodies
JP2022542805A (ja) メタロチオネイン抗体およびそれらの使用
TWI668010B (zh) 使用ｇｌｐ－１及抗ｉｌ－２１治療糖尿病
EA048509B1 (ru) Способы лечения диабета, гепатита и/или воспалительного заболевания печени
HK40040177B (en) Metallothionein inhibitors for treating diabetes, hepatitis, and/or inflammatory liver disease
HK40040177A (en) Metallothionein inhibitors for treating diabetes, hepatitis, and/or inflammatory liver disease
US20230020626A1 (en) Compositions and methods for treating obesity and hyperphagia
JP2020073501A (ja) Ｇｌｐ−１及び抗ｉｌ−２１を使用した１型糖尿病の治療

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230309

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230612

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240111

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240312

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240408

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240507

R150 Certificate of patent or registration of utility model

Ref document number: 7486423

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150